CD274 and gastric cancer: An analysis of 3% of 1581 advanced unresectable HER2-negative GC/GEJC patients (with MSI-H status) in the CheckMate649 study showed that regardless of PD-L1 expression status, MSI-H subgroup patients had higher OS benefits when compared to patients who had chemotherapy alone (63).